The Concise Guide to PHARMACOLOGY 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/ doi/10.1111/bph.12444/full.
An Introduction to Nuclear Hormone Receptors
Nuclear hormone receptors are specialised transcription factors with commonalities of sequence and structure, which bind as homo-or heterodimers to specific consensus sequences of DNA (response elements) in the promoter region of particular target genes. They regulate (either promoting or repressing) transcription of these target genes in response to a variety of endogenous ligands. Endogenous agonists are hydrophobic entities which, when bound to the receptor promote conformational changes in the receptor to allow recruitment (or dissociation) of protein partners, generating a large multiprotein complex.
Two major subclasses of nuclear hormone receptors with identified endogenous agonists can be identified: steroid and nonsteroid hormone receptors. Steroid hormone receptors function typically as dimeric entities and are thought to be resident outside the nucleus in the unliganded state in a complex with chaperone proteins, which are liberated upon agonist binding. Migration to the nucleus and interaction with other regulators of gene transcription, including RNA polymerase, acetyltransferases and deacetylases, allows gene transcription to be regulated. Nonsteroid hormone receptors typically exhibit a greater distribution in the nucleus in the unliganded state and interact with other nuclear hormone receptors to form heterodimers, as well as with other regulators of gene transcription, leading to changes in gene transcription upon agonist binding.
Selectivity of gene regulation is brought about through interaction of nuclear hormone receptors with particular consensus sequences of DNA, which are arranged typically as repeats or inverted palindromes to allow accumulation of multiple transcription factors in the promoter regions of genes.
1A. Thyroid Hormone Receptors
Overview: Thyroid hormone receptors (TRs, nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [3] ) are nuclear hormone receptors of the NR1A family, with diverse roles regulating macronutrient metabolism, cognition and cardiovascular homeostasis. TRs are activated by thyroxine (T4) and thyroid hormone (T3). Once activated by a ligand, the receptor acts as a transcription factor either as a monomer, homodimer or heterodimer with members of the retinoid X receptor family. NH-3 has been described as an antagonist at TRs with modest selectivity for TRβ [4] .
Nomenclature
Thyroid hormone receptor-α Thyroid hormone receptor-β Systematic nomenclature NR1A1 NR1A2
HGNC, UniProt THRA, P10827 THRB, P10828
Rank order of potency T3 > T4 T3 > T4
Selective agonists (pKi) -GC-1 (pKd 10.17) [2, 5] Comments: An interaction with integrin αVβ3 has been suggested to underlie plasma membrane localization of TRs and non-genomic signalling [1] . One splice variant, TRα2, lacks a functional DNA-binding domain and appears to act as a transcription suppressor.
Although radioligand binding assays have been described for these receptors, the radioligands are not commercially available. 
1B. Retinoic acid receptors
Overview: Retinoic acid receptors (nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [8] ) are nuclear hormone receptors of the NR1B family activated by the vitamin A-derived agonists all-trans-retinoic acid (ATRA) and 9-cis-retinoic acid, and the RAR-selective synthetic agonists TTNPB and adapalene. Comments: Ro 41-5253 has been suggested to be a PPARγ agonist [17] . LE135 is an antagonist with selectivity for RARα and RARβ compared with RARγ [14] . [9] is a family-selective antagonist.
Further reading
Bour G, Lalevée S, Rochette-Egly C. (2007 Comments: As with the estrogen receptor antagonists, many agents show tissue-selective efficacy (e.g. [20, 34, 36] ). Agonists with mixed activity at PPARα and PPARγ have also been described (e.g [24, 26, 43] ). 
1D. Rev-Erb receptors
Overview: Rev-erb receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [45] ) have yet to be officially paired with an endogenous ligand, but are thought to be activated by heme.
Endogenous agonists (pKi) heme ( 
1F. Retinoic acid-related orphans
Overview: Retinoic acid receptor-related orphan receptors (ROR, nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [50] ) have yet to be assigned a definitive endogenous ligand, although RORα may be synthesized with a 'captured' agonist such as cholesterol [52] [53] .
Nomenclature RAR-related orphan receptor-α RAR-related orphan receptor-β RAR-related orphan receptor-γ 
2A. Hepatocyte nuclear factor-4 receptors
Overview: Hepatocyte nuclear factor-4 receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [85] ) have yet to be officially paired with an endogenous ligand, although linoleic acid has been described to activate HNF4α receptors. 
Nomenclature

2B. Retinoid X receptors
Overview: Retinoid X receptors (nomenclature as agreed by NC-IUPHAR Committee on Nuclear Receptors, [90] ) are NR2B family members activated by 9-cis-retinoic acid and the RXR-selective agonists bexarotene and LG100268, sometimes referred to as rexinoids. UVI3003 [93] and HX531 [89] have been described as a pan-RXR antagonists. These receptors form RXR-RAR heterodimers and RXR-RXR homodimers [88, 92] .
Nomenclature
Retinoid X receptor-α Retinoid X receptor-β Retinoid X receptor-γ 
2C. Testicular receptors
Overview: Testicular receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [94] ) have yet to be officially paired with an endogenous ligand, although testicular receptor 4 has been reported to respond to retinoids.
Nomenclature Testicular receptor 2 Testicular receptor 4
Systematic nomenclature NR2C1 NR2C2
Endogenous agonists (pKi) -all-trans-retinoic acid (Selective) [96] , retinol (Selective) [96] Comment Forms a heterodimer with TR4; gene disruption appears without effect on testicular development or function [95] Forms a heterodimer with TR2 
2E. Tailless-like receptors
Overview: Tailless-like receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [97] ) have yet to be officially paired with an endogenous ligand. 
Nomenclature
2F. COUP-TF-like receptors
Overview: COUP-TF-like receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [100] ) have yet to be officially paired with an endogenous ligand.
Gene disruption is perinatally lethal [102] Gene disruption is embryonically lethal [101] Gene disruption impairs CNS development [103] Further reading 
4A. Nerve growth factor IB-like receptors
Overview: Nerve growth factor IB-like receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [110] ) have yet to be officially paired with an endogenous ligand. 
5A. Fushi tarazu F1-like receptors
Overview: Fushi tarazu F1-like receptors (nomenclature as agreed by NC-IUPHAR committee on nuclear hormone receptors [114] ) have yet to be officially paired with an endogenous ligand. Comments: R,R-THC exhibits partial agonist activity at ERα [134, 146] . Estrogen receptors may be blocked non-selectively by tamoxifen and raloxifene and labelled by [ 3 H]17β-estradiol and [ 3 H]tamoxifen. Many agents thought initially to be antagonists at estrogen receptors appear to have tissue-specific efficacy (e.g. tamoxifen is an antagonist at estrogen receptors in the breast, but is an agonist at estrogen receptors in the uterus), hence the descriptor SERM (selective estrogen receptor modulator) or SnuRM (selective nuclear receptor modulator). Y134 has been suggested to be an ERα-selective estrogen receptor modulator [136] . groups. These groups appear to promote binding of PR to DNA with different efficacies and evoke distinct conformational changes in the receptor, leading to a transcription-neutral complex [122, 129] . Mutations in AR underlie testicular feminization and androgen insensibility syndromes, spinal and bulbar muscular atrophy (Kennedy's disease).
3C. 3-Ketosteroid receptors
